Shows
What's it Worth? A Journal Club PodcastS3E5 (#21) Empagliflozin Meets MASLD: Hope, Hype, or Hypothesis?Welcome back to What’s it Worth! Join your hosts, Dr. Diana Langworthy and Dr. Peyton Braun (PGY1 Pharmacy Resident), as we sift through strengths and limitations of at trial assessing the effects of empagliflozin on nonalcoholic fatty liver disease. The authors sought to quantify the impact of Sodium Glucose Cotransporter 2 - inhibitors (SGLT2i's) on Metabolic Dysfunction Associated Liver Disease (MASLD). This episode is full of EBP detective moments - dissecting trial language to get a clear picture of the story. Let's dive in and see what its worth! Key Points MASLD is a condition marked...2025-06-0350 min
AJHP VoicesEthical Dimensions of the Opioid CrisisWilliam Zellmer talks with Timothy P. Stratton and Heather L. Blue about the ethical dimensions of the opioid crisis.
Recorded June 4, 2017.
AJHP is the official journal of the American Society of Health-System Pharmacists.
www.ajhpvoices.org2017-10-1024 min